Release 300 mg/ml, Solution for Injection

Country: Велика Британија

Језик: Енглески

Извор: VMD (Veterinary Medicines Directorate)

Активни састојак:

Pentobarbital Sodium

Доступно од:

WDT-Wirtschaftsgenossenschaft deutscher Tieraerzte eG

АТЦ код:

QN51AA01

INN (Међународно име):

Pentobarbital Sodium

Фармацеутски облик:

Solution for injection

Тип рецептора:

POM-V - Prescription Only Medicine – Veterinarian

Терапеутска група:

Cage Birds, Cats, Cattle, Chickens, Dogs, Frog, Guinea Pig, Hamster, Hare, Horses, Lizard, Mink, Mouse, Pigeon (non-food producing), Pigs, Polecat, Rabbits, Rat, Snake, Tortoise

Терапеутска област:

Neurological Agent euthanasia agent

Статус ауторизације:

Authorized

Датум одобрења:

2008-08-05

Карактеристике производа

Revised: October 2019
AN: 00331/2019
Page 1 of 7
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Release 300 mg/ml, solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCE:
pentobarbital sodium
300 mg
EXCIPIENT:
patent blue V
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection
A clear, blue solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Horses, ponies, cattle, swine, dogs, cats, minks, polecats, hares,
rabbits, guinea
pigs, hamsters, rats, mice, chicken, pigeons, birds, snakes,
tortoises, lizards, frogs
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For euthanasia in animals.
4.3
CONTRAINDICATIONS
Do not use in animals intended for human or animal consumption.
Do not use for anaesthetic purposes.
Do not use for intracoelomic injection in chelonia as the time to
death may be
unnecessarily prolonged compared with intravenous administration.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Carcasses of animals euthanised with this product should be disposed
of in
accordance with national legislation.
Carcasses of animals euthanised with this product should not be fed to
other
animals due to the risk of secondary intoxication.
Revised: October 2019
AN: 00331/2019
Page 2 of 7
The intraperitoneal route of administration may cause a prolonged
onset of action
with an increased risk of adverse effects noted in 4.6. Prior sedation
is advisable.
The intrapulmonary route of administration may cause a prolonged onset
of action
with an increased risk of adverse effects noted in 4.6 and should be
reserved for
cases where other routes of administration are not possible. Prior
sedation is
mandatory before this route of administration is employed.
When euthanasia of poikilotherms is undertaken, the animal must be
maintained
at its preferred optimum temperature, otherwise efficacy may be
unreliable.
Species appropriate measures (e.g. pithing) should be taken to ensure
that
euthanasia is complete in orde